News

Purdue Pharma announces availability of insomnia drug

Purdue Pharma has announced the availability of Intermezzo sublingual tablet CIV in 1.75mg and 3.5mg dosage strengths for insomnia characterized by middle-of-the-night awakenings followed by difficulty returning to sleep. Intermezzo (zolpidem tartrate), which contains...

VitalMax unveils advanced vitamin formula to maintain glucose levels

VitalMax Vitamins, a nutritional supplement company, has introduced Diabetrol, an advanced vitamin formula to keep glucose levels in check. Diabetrol consists of 16 natural vitamin ingredients, formulated to help provide blood sugar protection. The advanced...

PolyTherics joins Spirogen to develop antibody-drug conjugates

PolyTherics has executed a research collaboration deal with Spirogen to develop antibody-drug conjugates (ADCs) for the treatment of cancer. Under the collaboration, the companies will produce ADCs by integrating PolyTherics' proprietary TheraPEG linker technology...

Scientists map new mechanism in brain’s barrier tissue

Researchers at the University of Copenhagen have documented a previously unknown biological mechanism in the brain's most important line of defence: the blood-brain barrier. Scientists now know that the barrier helps maintain a delicate balance of glutamate, a...

IMI funds platform to discover new medicines

The Innovative Medicines Initiative has officially announced the construction of an EU-wide public-private partnership, the "European Lead Factory", to combine a comprehensive collection of candidate drug molecules - a Joint European Compound Collection - with an industry-like European...

Schwartz Center Receives $500,000 Grant from the Amgen Foundation

The Schwartz Center for Compassionate Healthcare, a Boston-based nonprofit dedicated to strengthening the relationship between patients and their healthcare providers, today announced it has received a $500,000 grant from the Amgen Foundation. This grant...

GSK announces submissions for two influenza vaccines

GSK has submitted US and EU regulatory applications seeking approval of a quadrivalent influenza vaccine for the "active immunisation of adults and children from 3 years of age for the prevention of influenza disease caused by influenza virus...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Must read